SSY Group Limited Announces Strategic Collaboration with Opterion Health AG for Exclusive License of Groundbreaking Peritoneal Dialysis Drug OPT101
Key Points Investors Must Know
- SSY Group Limited (HKEX: 2005), through its wholly-owned subsidiary Shijiazhuang No. 4 Pharmaceutical Co., Ltd., has signed a Letter of Intent (LOI) with Opterion Health AG, a Swiss-based biopharma company.
- The LOI pertains to an exclusive license for OPT101, a novel, non-glucose-based osmotic agent for peritoneal dialysis, classed as a Class 1 innovative drug.
- OPT101 is the first innovation in peritoneal dialysis in over 30 years and aims to eliminate glucose-related complications, representing a major breakthrough in renal care.
- The exclusive license covers research, development, manufacturing, and sales of OPT101 in Mainland China (excluding Hong Kong, Macau, and Taiwan) through 2038.
- Shijiazhuang No. 4 will also have priority rights for future licenses in Hong Kong, Taiwan, and Russia on the same terms and conditions.
- Formal agreement is expected by Q3 2026, contingent on positive Phase I clinical trial results from the European Medicines Agency (EMA).
- The LOI includes a Priority Cooperation Right for SSY Group to match or surpass any third-party offers before 30 September 2026, extendable if trial results are delayed.
- Other than confidentiality and non-compete clauses, the LOI is non-binding and effective for three months from signing or until a term sheet is agreed.
- Opterion Health AG and its owners are independent third parties with no connection to SSY Group.
Detailed Overview and Implications for Shareholders
SSY Group Limited has taken a significant step to strengthen its innovation pipeline by securing an exclusive pathway to commercialize OPT101, an advanced therapy for peritoneal dialysis patients. This move positions SSY at the forefront of renal care innovation in China, tapping into a rapidly expanding market with substantial unmet needs.
OPT101 is a non-glucose-based osmotic driver, addressing critical issues such as metabolic distress and complications that have plagued peritoneal dialysis patients for decades. If successful, the product could vastly improve patient outcomes and quality of life, potentially capturing a significant share of a large and growing market.
The agreement ensures that, subject to successful clinical trials and a formal agreement, SSY will hold the exclusive rights to develop, manufacture, and sell OPT101 in Mainland China until 2038. The company also secures a right of first refusal for future expansion into Hong Kong, Taiwan, and Russia.
Under the LOI, SSY is protected by a Priority Cooperation Right, giving it the first option to cooperate with Opterion should third-party interest arise. This right expires on 30 September 2026 unless extended due to delayed clinical results.
Importantly, the LOI is non-binding except for certain key clauses and is set to last for three months unless superseded by a term sheet or formal agreement. Investors should note that a definitive agreement has not yet been reached, and the possible collaboration remains subject to successful negotiation and the outcome of ongoing clinical trials.
Potential Impact on Share Price
- This announcement reflects SSY’s forward-looking strategy and commitment to innovation, which could significantly enhance its growth prospects and competitive positioning.
- Should the collaboration proceed and clinical trials prove successful, SSY could realize considerable commercial benefits and market expansion, potentially driving share price appreciation.
- Shareholders and potential investors should be aware that there is still risk, as the collaboration may not materialize if a formal agreement is not executed or if clinical results are unsatisfactory.
Shareholders are advised to exercise caution when dealing in the Company’s shares as the potential collaboration is not yet finalized and may or may not proceed.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making any investment decisions. The information is based on the official company announcement as of 15 June 2026 and may change as further updates are released.
【粵語版】SSY集團有限公司自願性公告：與Opterion Health AG簽署創新藥物OPT101獨家授權意向書
投資者必須關注的重點
- SSY集團有限公司（港交所：2005）旗下全資子公司石家莊四藥有限公司，與瑞士生物醫藥公司Opterion Health AG簽署了意向書（LOI）。
- 此意向書涉及一項針對OPT101（創新一類藥物）的獨家授權，該藥為一種全新非葡萄糖型滲透劑，用於腹膜透析。
- OPT101為腹膜透析領域30年來首個重大創新，有望解決傳統葡萄糖基滲透劑帶來的併發症問題。
- 授權內容涵蓋中國大陸（不包括港澳台）對OPT101的研發、生產和銷售權，期限至2038年。
- 石家莊四藥亦獲得未來在香港、台灣及俄羅斯的優先授權權利。
- 正式協議預計於2026年第三季度簽訂，前提是歐洲藥監局（EMA）一期臨床數據達標。
- LOI設有優先合作權，如Opterion有意引入第三方，石家莊四藥可優先選擇是否加入合作，該權利至2026年9月30日止（如臨床數據延遲可延期）。
- 除保密及競業禁止等條款外，LOI並無法律約束力，有效期為三個月或至協議簽署為止。
- Opterion及其實益擁有人與SSY集團並無關聯，屬獨立第三方。
詳細內容及對股東之啟示
SSY集團此次與Opterion合作，有望進一步加強創新藥物研發實力，並搶佔中國腹膜透析市場優勢。OPT101突破性地解決了傳統腹膜透析用藥的副作用，有潛力顯著改善腎衰竭患者的治療效果和生活質素，市場潛力巨大。
此協議意味著（如臨床進展及最終協議順利簽訂）SSY將獨家持有OPT101於中國大陸的商業化權利至2038年，並有優先機會拓展至港、台及俄羅斯市場。
LOI中的優先合作權保障了SSY的合作主導權，遇有第三方加入時可優先選擇參與。值得注意的是，LOI除若干條款外並無約束力，且最終合作與否仍視臨床結果及正式協議進展而定。
對股價的潛在影響
- 本公告彰顯SSY集團進取創新戰略，倘若合作順利及臨床成功，將有望帶動公司增長並提升競爭力，對股價有正面影響。
- 不過，合作尚未落實，亦存臨床風險，投資者須留意相關不確定性。
公司提醒股東及潛在投資者，合作尚未最終落實，請審慎處理公司股票。
免責聲明：本文僅作資訊參考，並不構成任何投資建議。投資者應自行研究及諮詢專業意見，方作投資決定。資訊以2026年6月15日公司公告為依據，後續如有更新請留意公司進一步公告。
